194 related articles for article (PubMed ID: 26459903)
1. Biofilms of Pathogenic Nontuberculous Mycobacteria Targeted by New Therapeutic Approaches.
Aung TT; Yam JK; Lin S; Salleh SM; Givskov M; Liu S; Lwin NC; Yang L; Beuerman RW
Antimicrob Agents Chemother; 2016 Jan; 60(1):24-35. PubMed ID: 26459903
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel antimycobacterial drug therapy in biofilm of pathogenic nontuberculous mycobacterial keratitis.
Aung TT; Chor WHJ; Yam JKH; Givskov M; Yang L; Beuerman RW
Ocul Surf; 2017 Oct; 15(4):770-783. PubMed ID: 28662943
[TBL] [Abstract][Full Text] [Related]
3. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.
Abshire R; Cockrum P; Crider J; Schlech B
Clin Ther; 2004 Feb; 26(2):191-6. PubMed ID: 15038942
[TBL] [Abstract][Full Text] [Related]
4. In vitro antibiotic susceptibility of rapidly growing nontuberculous mycobacteria isolated from patients with microbial keratitis.
Reddy AK; Garg P; Babu KH; Gopinathan U; Sharma S
Curr Eye Res; 2010 Mar; 35(3):225-9. PubMed ID: 20373881
[TBL] [Abstract][Full Text] [Related]
5. Biofilm formation and biocide susceptibility testing of Mycobacterium fortuitum and Mycobacterium marinum.
Bardouniotis E; Ceri H; Olson ME
Curr Microbiol; 2003 Jan; 46(1):28-32. PubMed ID: 12432460
[TBL] [Abstract][Full Text] [Related]
6. Nontuberculous mycobacteria pathogenesis and biofilm assembly.
Sousa S; Bandeira M; Carvalho PA; Duarte A; Jordao L
Int J Mycobacteriol; 2015 Mar; 4(1):36-43. PubMed ID: 26655196
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Sarayba MA; Shamie N; Reiser BJ; Sweet PM; Taban M; Graff JM; Kesler-Diaz A; Osann KE; McDonnell PJ
J Cataract Refract Surg; 2005 Jul; 31(7):1396-402. PubMed ID: 16105613
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic susceptibility pattern of rapidly growing mycobacteria.
Gayathri R; Therese KL; Deepa P; Mangai S; Madhavan HN
J Postgrad Med; 2010; 56(2):76-8. PubMed ID: 20622384
[TBL] [Abstract][Full Text] [Related]
9. Mycobacterium fortuitum and Mycobacterium chelonae biofilm formation under high and low nutrient conditions.
Hall-Stoodley L; Keevil CW; Lappin-Scott HM
J Appl Microbiol; 1998 Dec; 85 Suppl 1():60S-69S. PubMed ID: 21182694
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis.
Hyon JY; Joo MJ; Hose S; Sinha D; Dick JD; O'Brien TP
Arch Ophthalmol; 2004 Aug; 122(8):1166-9. PubMed ID: 15302657
[TBL] [Abstract][Full Text] [Related]
11. In vitro bactericidal activity of antibiotic combinations against clinical isolates of Mycobacterium chelonae.
Cremades R; Santos A; Rodríguez JC; Garcia-Pachon E; Ruiz M; Royo G
J Chemother; 2008 Feb; 20(1):43-7. PubMed ID: 18343742
[TBL] [Abstract][Full Text] [Related]
12. Biofilm formation by the rapidly growing mycobacterial species Mycobacterium fortuitum.
Hall-Stoodley L; Lappin-Scott H
FEMS Microbiol Lett; 1998 Nov; 168(1):77-84. PubMed ID: 9812366
[TBL] [Abstract][Full Text] [Related]
13. Nontuberculous mycobacteria: susceptibility pattern and prevalence rate in Shanghai from 2005 to 2008.
Wang HX; Yue J; Han M; Yang JH; Gao RL; Jing LJ; Yang SS; Zhao YL
Chin Med J (Engl); 2010 Jan; 123(2):184-7. PubMed ID: 20137367
[TBL] [Abstract][Full Text] [Related]
14. Generation of resistant mutants of Mycobacterium chelonae and Mycobacterium fortuitum after exposure to subinhibitory concentrations of clarithromycin and moxifloxacin.
Rodriguez JC; Garcia-Pachon E; Flores E; Escribano I; Ruiz M; Royo G
J Chemother; 2007 Oct; 19(5):599-601. PubMed ID: 18073162
[No Abstract] [Full Text] [Related]
15. Activity of various drugs alone or in combination against Mycobacterium fortuitum.
Santos A; Cremades R; Rodríguez JC; Garcia-Pachon E; Ruiz M; Royo G
J Infect Chemother; 2010 Feb; 16(1):64-7. PubMed ID: 20063030
[TBL] [Abstract][Full Text] [Related]
16. Mycobacterium avium Possesses Extracellular DNA that Contributes to Biofilm Formation, Structural Integrity, and Tolerance to Antibiotics.
Rose SJ; Babrak LM; Bermudez LE
PLoS One; 2015; 10(5):e0128772. PubMed ID: 26010725
[TBL] [Abstract][Full Text] [Related]
17.
Shoen C; Benaroch D; Sklaney M; Cynamon M
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858221
[TBL] [Abstract][Full Text] [Related]
18. Nontuberculous Mycobacteria: Skin and Soft Tissue Infections.
Gonzalez-Santiago TM; Drage LA
Dermatol Clin; 2015 Jul; 33(3):563-77. PubMed ID: 26143432
[TBL] [Abstract][Full Text] [Related]
19. Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis.
Moshirfar M; Meyer JJ; Espandar L
J Cataract Refract Surg; 2007 Nov; 33(11):1978-81. PubMed ID: 17964409
[TBL] [Abstract][Full Text] [Related]
20. Screening for sterilizing activity of antibiotic combinations in an acid model of rapidly growing mycobacteria during the stationary phase of growth.
Cremades R; Santos A; Rodríguez JC; García-Pachón E; Ruiz M; Escribano I; Royo G
Chemotherapy; 2009; 55(2):114-8. PubMed ID: 19155619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
